Achilles Therapeutics PLC (ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ACHL Nasdaq 8731 https://www.achillestx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Achilles Therapeutics PLC (ADR

Achilles Therapeutics Recognized with the 2022 PING Innovation Award - Jun 21st, 2022 12:30 pm
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation - Jun 6th, 2022 12:40 pm
Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights - May 10th, 2022 11:00 am
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma - May 9th, 2022 11:00 am
Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors - May 4th, 2022 12:00 pm
Achilles Therapeutics to Present at Upcoming Conferences - May 3rd, 2022 12:00 pm
Center for Breakthrough Medicines' latest deal is with London biotech firm Achilles Therapeutics - Apr 14th, 2022 3:27 pm
The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy Powerhouse - Apr 12th, 2022 11:30 am
Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US - Apr 12th, 2022 11:30 am
Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting - Apr 4th, 2022 12:00 pm
Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference - Mar 8th, 2022 1:00 pm
Achilles Therapeutics Selects Netrality’s 401 North Broad for United States Headquarters - Mar 1st, 2022 2:00 pm
Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights - Mar 1st, 2022 12:02 pm
Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D. - Feb 7th, 2022 12:30 pm
Achilles Therapeutics Provides Business Update and Outlook for 2022 - Jan 13th, 2022 12:30 pm
Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans - Dec 28th, 2021 9:09 am
Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference - Dec 21st, 2021 1:00 pm
Achilles Therapeutics Added to the NASDAQ Biotechnology Index - Dec 20th, 2021 1:00 pm
Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens - Dec 9th, 2021 12:00 pm
Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS™ Process 2 Manufacturing - Nov 12th, 2021 12:00 pm